Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents

Area of Science:

• Immunology
• Virology
• Medicinal Chemistry

Background:

• HIV latency in CD4+ T cells is a major obstacle to curing infection with antiretroviral therapy alone.
• Latency Reversing Agents (LRAs) can reactivate HIV expression, potentially leading to viral clearance.
• Bryostatin analogs (bryologs) were developed to improve synthetic accessibility, tolerability, and efficacy for HIV latency reversal.

Purpose of the Study:

• To comparatively evaluate the performance of lead bryolog compounds.
• To investigate structure-function relationships of bryolog modifications in primary cells.
• To assess the potential of bryologs as preclinical candidates for HIV latency reversal.

Main Methods:

• Comparative analysis of lead bryologs in primary cells.
• Assessment of effects on HIV entry receptor expression.
• Measurement of proinflammatory cytokine induction.
• Evaluation of inhibition of short-term HIV replication.
• Testing synergy with histone deacetylase inhibitors for latency reversal.

Main Results:

• Lead bryologs demonstrated effects on reducing cell surface HIV entry receptors.
• Bryologs induced proinflammatory cytokines and inhibited short-term HIV replication.
• These compounds synergized with histone deacetylase inhibitors to reverse HIV latency.
• Structure-function insights were gained regarding A- and B-ring bryolog modifications.

Conclusions:

• Bryologs represent promising leads for preclinical development in HIV latency reversal.
• Simplified bryostatin analogs offer potential for improved HIV cure strategies.
• Further research into bryologs could advance therapeutic approaches for HIV infection.